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Abstract 
Seneca virus A (SVA) and porcine reproductive and respiratory syndrome virus (PRRSV) have 
caused significant economic losses to swine production in the United States. Recently, 
contaminated feed and feed ingredients have been considered risk factors for swine virus 
transmission. The use of chemical feed additives has been discussed as one potential management 
strategy to mitigate this risk. The objective of this study was to evaluate the efficacy of medium 
chain fatty acid-based (MCFA) and formaldehyde-based (FORMALD) liquid antimicrobials 
against SVA and PRRSV in a cell culture model. Viral stocks of SVA and PRRSV (106 50% tissue 
culture infectious dose per ml, TCID50/ml) were mixed with different concentrations of MCFA or 
FORMALD in minimum essential media. Ten-fold serial dilutions of each virus-mitigant mixture 
were performed in triplicate for inoculation onto confluent monolayers of porcine kidney (PK-15) 
and African green monkey kidney (MARC-145) cells for SVA and PRRSV, respectively. Viral 
titers after exposure to each mitigant were determined by the serial dilution endpoint method and 
calculated using the method of Reed and Muench. The differences between the titer of the control 
virus (no mitigant) and the mitigant-treated samples were used to measure antiviral activity. 
FORMALD reduced the titers of both SVA and PRRSV at concentrations above 0.6% and 0.15%, 
respectively. MCFA reduced the PRRSV titer at concentrations greater than 0.25%. No significant 
reduction of SVA titers were detected after exposure to MCFA up to 5%. This study provides 
evidence suggesting that both MCFA and FORMALD may be used as potential feed additives to 
mitigate the risk of SVA or PRRSV transmission through contaminated animal feed or ingredients.  
 
 
 
iv 
Table of Contents 
List of Figures ................................................................................................................................ vi 
List of Tables ............................................................................................................................... viii 
Acknowledgements ........................................................................................................................ ix 
Dedication ...................................................................................................................................... xi 
Chapter 1 - Literature review .......................................................................................................... 1 
1.1 Transboundary animal diseases ........................................................................................ 1 
1.2 Risk factor analysis for introduction of transboundary swine viruses .............................. 3 
1.2.1 Porcine epidemic diarrhea virus (PEDV) ...................................................................... 3 
1.3 Virus survival .................................................................................................................... 5 
1.3.1 Porcine reproductive and respiratory syndrome virus (PRRSV) ................................... 6 
1.3.2 Seneca virus A (SVA) .................................................................................................... 7 
1.4 Feed mitigation strategies ................................................................................................. 8 
1.4.1 Medium chain fatty acids (MCFA) ................................................................................ 8 
1.4.2. Formaldehyde ............................................................................................................... 9 
1.4.3 Advantages and disadvantages of chemical feed additives ......................................... 10 
Chapter 2 - Inactivation of Seneca virus A using medium-chain fatty acids and formaldehyde-
based feed additives in cell culture ........................................................................................ 13 
2.0 Introduction ..................................................................................................................... 13 
2.1 Seneca virus A ................................................................................................................ 13 
2.2 Why is SVA important .................................................................................................... 15 
2.3 Materials and Methods .................................................................................................... 16 
2.4 Results ............................................................................................................................. 18 
2.5 Discussion ....................................................................................................................... 23 
Chapter 3 - Inactivation of porcine reproductive and respiratory syndrome virus (PRRSV) using 
medium chain fatty acids (MCFAs) and Formaldehyde based feed additives in cell culture 25 
3.0 Introduction ..................................................................................................................... 25 
3.1 Porcine reproductive and respiratory syndrome virus .................................................... 25 
3.2 Why is PRRSV important ............................................................................................... 29 
3.3 Materials and Methods .................................................................................................... 31 
v 
3.4 Results ............................................................................................................................. 33 
3.5 Discussion ....................................................................................................................... 36 
Chapter 4 - Animal feed trial ........................................................................................................ 38 
4.0 Introduction ..................................................................................................................... 38 
4.1 Materials and Methods .................................................................................................... 39 
4.2 Results ............................................................................................................................. 40 
4.3 Conclusion ...................................................................................................................... 42 
Chapter 5 - References .................................................................................................................. 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
List of Figures 
Figure 1: Schematic illustration of mitigation strategies for potentially contaminated imported 
feed and/or feed ingredients to the U.S. ................................................................................ 12 
Figure 2: Genome and structure of Seneca virus A. ..................................................................... 14 
Figure 3: World distribution of SVA. Countries marked in blue have detected SVA cases in pigs.
 ............................................................................................................................................... 15 
Figure 4: PK-15 cell line treated with MCFAs (left) and FORMALD (right) after three days 
incubation period. Magnification of 200x. ........................................................................... 18 
Figure 5: PK-15 cells after being challenged with virus-mitigant mixture, SVA-MCFA (left) and 
SVA-FORMALD (right). Magnification of 200x. ............................................................... 19 
Figure 6: Dose response inactivation curve of FORMALD against SVA. ................................... 20 
Figure 7: Dose response inactivation curve of MCFA against SVA. Data is shown for titers after 
no incubation period. ............................................................................................................ 21 
Figure 8: Dose response inactivation curve of MCFA against SVA. Data is shown for titers after 
30 minutes of incubation. ...................................................................................................... 22 
Figure 9: Dose response inactivation curve of MCFA against SVA. Data is shown for titers after 
45 minutes of incubation. ...................................................................................................... 23 
Figure 10: The genome and structure of PRRSV. ........................................................................ 28 
Figure 11: World distribution of PRRSV. Countries marked in blue have detected PRRSV cases 
in pigs. ................................................................................................................................... 29 
Figure 12: MARC-145 cell line treated with MCFAs (left) and FORMALD (right) after three 
days incubation period. Magnification of 200x. ................................................................... 33 
Figure 13: MARC 145 cells after being challenged with virus-mitigant mixture, PRRSV-MCFA 
(left) and PRRSV-FORMALD (right). Magnification of 200x. ........................................... 34 
Figure 14: Dose response inactivation curve of FORMALD against PRRSV ............................. 35 
Figure 15: Dose response inactivation curve of MCFAs against PRRSV. ................................... 36 
Figure 16: Complete feed trial, the presence of green cells indicates infected cells by SVA. A)  
the positive control is the result of complete feed spiked with SVA b) negative control, the 
mock inoculation of complete feed with sterile normal saline c) MCFA-SVA treated cells d) 
FORMALD-SVA treated cells. Magnification of 200x. ...................................................... 41 
vii 
Figure 17: Complete feed trial, dose response inactivation curve of SVA-complete feed-mitigants 
and controls (positive control and negative control). ............................................................ 42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
List of Tables 
Table 1: The proposed mechanism of MCFAs and formaldehyde and their effects on example 
viruses that are rendered inactive by the mitigants. .............................................................. 10 
Table 2: Estimated Annual Cost of PRRS in the U.S. .................................................................. 30 
 
  
ix 
Acknowledgements 
First and foremost, I would like to thank God, almighty who my strength lies. 
I would like to extend my sincere gratitude to my major professor Dr. Megan Niederwerder for 
allowing me to work on this project. I'm thankful for her guidance, support, and advice in this 
project and academic life.  
My sincere gratitude goes to my committee members, Dr. Raymond R.R Rowland and Dr. M.M 
Chengappa for their advice and support throughout this project.  
My special thanks go to Ana Stoian for teaching me lab techniques that were required for this 
project. I would like to thank everyone in Megan and Rowlands's lab for being patient, 
supportive and helpful during my learning process. This work would have not been done without 
their support. 
My sincere thanks go to Tesfaalem Sebhantu who helped me to get this opportunity and 
Dr.Walter C. Renberg for his help during my adjustment. I would like to appreciate their time, 
endless supports and guidance.  
I would like to thank Dr. TG Nagaraja for his help to make sure that I get this opportunity.  
I would like to thank my friends, Naemi Shadipeni, Dinali Krishani, Changin Oh, Pradyumna, 
Lucia and Robert for being supportive throughout this project.  
I would also like to thank and appreciate everyone who helped me during my studies.  
My sincere gratitude goes to my family for their support, love, guidance and most importantly 
their continuous prayers throughout my life.  
x 
My sincere grateful go to the department of diagnostic medicine and pathobiology for funding 
support. 
  
xi 
Dedication 
I dedicate this project to my family who have been supportive throughout my life.  
 
 
1 
Chapter 1 - Literature review 
1.1 Transboundary animal diseases   
Transboundary animal diseases (TADs) are among the greatest threats to animal health and 
livestock agriculture throughout the world. As defined by the United Nations Food and 
Agricultural Organization (FAO), TADs are of significant economic, trade and/or food security 
importance for numerous countries (Domenech et al. 2006). These diseases have the potential to 
spread to other countries and can reach epidemic proportions. Control, management, and 
exclusion requires cooperation between all affected countries. These diseases are categorized 
under List A diseases by the World Organization for Animal Health (OIE) as having had direct 
and indirect impacts on the economies of both developed and developing countries (Domenech 
et al. 2006). TADs are characterized by several factors, including 1) the severity of losses caused 
by the disease, 2) the distance over which these diseases can be transmitted by livestock or 
livestock by-products, 3) the speed of transmission, 4) the susceptibility of each disease to 
various control measures, 5) the availability of accurate diagnostics testing, and 6) the current 
scientific knowledge of the disease (Domenech et al. 2006; Rossiter and Hammadi 2009). 
Historically, the OIE has reported on the global cases of economic and livestock production 
losses caused by TADs worldwide. For example, in 1997, there was an outbreak of foot and 
mouth disease (FMD) in Taiwan. To contain and eliminate the disease, 3,850,746 pigs at 6,147 
infected pig farms were culled within two months (Yang et al. 1999a). This outbreak cost 
Taiwan an estimated $378.6 million U.S. dollars, with economic losses associated with the cost 
of disease control and containment. Additionally, costs associated with eliminating pork 
exported to Japan from Taiwan was around $1.6 billion U.S. dollars (Yang et al. 1999). In that 
same year (1997), the Netherlands encountered significant economic losses from pig production 
2 
by culling of 429 infected herd and about 1300 at-risk herds were slaughtered due to an outbreak 
of classical swine fever (CSF) (Stegeman et al. 2000). As another example, the FMD outbreak of 
2001 in the United Kingdom led to tremendous economic losses, including those directly and 
indirectly related to agriculture and related industries, up to 3.1 billion Pounds Sterling 
(Thompson et al. 2002). The U.S. has remained free of FMD for almost a century. An FMD 
outbreak in the U.S. would greatly affect the export market, as the U.S. is one of the largest 
exporters of pork and beef in the world (Hayes et al. 2011). Most of these costs will be 
associated with attempts to eliminate the virus by culling both infected and at-risk herds. Costs 
due to market losses have been estimated to be approximately $14 million in the U.S. due to an 
FMD outbreak (Paarlberg, Lee, & Seitzinger, 2002). TADs have affected the U.S. market by 
directly affecting production and the cost of managing the outbreak. This, in particular, is 
evidenced by an outbreak of porcine epidemic diarrhea virus (PEDV) in the U.S. in 2013 
(Stevenson et al. 2013) and the current cost of porcine reproductive and respiratory syndrome 
virus (PRRSV), a disease which has emerged and re-emerged in U.S. swine over the past 3 
decades (Charerntantanakul 2012; Nelsen, Murtaugh, and Faaberg 1999). First, the PEDV 
outbreak impacted the supply of pork products due to the significant loss of pigs to disease; 
within one year after the initial PEDV case had been detected, an estimated 7 million pigs had 
died due to PED (Schulz and Tonsor 2015). This resulted in a substantial animal welfare and 
economic impact to pork producers. Despite the substantial effect of PED on U.S. pork 
production over the last several years, PRRSV has been widely considered to be the costliest 
disease of swine production in the U.S. since its introduction. PRRSV is estimated to cost the 
U.S. more than $600 million annually, equivalent to $1.8 million/day (Holtkamp et al., 2012). 
Furthermore, Seneca virus A (SVA) is a third disease of importance to the U.S. swine industry 
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due to its emergence as a cause of vesicular disease since 2015 and its important clinical 
similarities to FMD (Baker et al. 2017; Raquel Arruda Leme et al. 2019; Segalés et al. 2017).  
Globally, there are many factors that can contribute to the spread of TADs to new areas, 
countries or regions. Specifically, human travel, live animal movement, animal by-product 
transport, fomites such as transportation vehicles, agricultural equipment, and the more recently 
recognized movement of contaminated animal feed and feed ingredients have all been described 
as potential risk factors for pathogen introduction and spread (Bowman et al. 2015; S. A. Dee et 
al. 2018). 
 1.2 Risk factor analysis for introduction of transboundary swine viruses 
The U.S. swine industry first recognized the significant role that imported and distributed animal 
feed and ingredients may play in pathogen introduction and transmission after the 2013 outbreak 
of PEDV. The initial introduction and subsequent spread of PEDV was linked with contaminated 
swine feed (S. Dee et al. 2014). Consequently, most studies related to virus transmission and 
spread in feed have been performed on PEDV, which may serve as a model for other swine 
pathogens of transboundary significance such as PRRSV and SVA. 
 1.2.1 Porcine epidemic diarrhea virus (PEDV) 
PEDV is an enveloped positive-sense, single-stranded RNA virus belonging to the family 
Coronaviridae and the genus Alphacoronavirus (Stevenson et al. 2013). It is a moderately sized 
virus with a genome of 28kb and is the causative agent of porcine epidemic diarrhea (PED) (Lee 
2015). Since the introduction of PEDV in the U.S., it quickly became widespread in over 200 
herds in thirteen states (Lee 2015). Within 1 year, PED caused major economic losses and the 
loss of approximately 10% of the swine population due to mortality (Schulz and Tonsor 2015; 
Stevenson et al. 2013). 
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 PEDV was later reported in Canada and Mexico by 2014 (Lee 2015). Following PEDV’s 
introduction and spread in the U.S., many sources of transmission were proposed including 
aerosol, contaminated transport vehicles, human movement, breaches in biosecurity, and other 
fomites  (Lowe et al. 2014; Scott et al. 2016). Similarly, in Canada, studies involving animal 
feeds and animal by-products demonstrating PEDV positivity provided a potential clue on the 
role of feed in PEDV introduction to the country (Pasick et al., 2014). Following the recognition 
of contaminated animal feed as a potential risk for virus transmission, several studies have been 
performed to help define this risk. One such study included feeding naïve piglets contaminated 
porcine by-product (Opriessnig, Xiao, Gerber, Zhang, & Halbur, 2014), however another study 
done by (Pasick et al., 2014) indicated that excretion from piglets that were fed PEDV positive 
feed, tested positive for PEDV for over 9 days post-infection. Following these studies, the 
hypothesis was developed that contaminated porcine plasma (spray-dried plasma) included in 
feed had the potential to transmit the virus through natural feeding conditions. Dee et al.,2014 
proved the concept of PEDV contaminated animal feed being capable of inducing PEDV 
infection in naïve piglets. These studies brought attention to whether contaminated feed and/or 
feed ingredients frequently imported to the U.S. from high-risk countries could have served as 
sources of PEDV introduction to the country. Whole-genome sequence analysis showed that the 
U.S. PEDV isolate had 96.6-99.5% identity with all known PEDV strains, and  over 99% 
similarity with that of 2011-2012 Chinese strains, suggesting the possibility that the U.S. PEDV 
strain may have been introduced from China (Stevenson et al., 2013). Another important study 
showed that the minimum infectious dose of PEDV in feed was 5.6 × 101 TCID50/g and that feed 
with a PCR cycle threshold value of 37 was sufficient to cause infection in piglets (Schumacher 
et al., 2016). Importantly, this information revealed the low dose of PEDV required for infection 
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and highlighted an important pathogenesis trait of the virus which may have contributed to its 
rapid spread. Overall, these findings supported the risk of contaminated feed as a risk factor for 
the introduction and transmission of PEDV and exposed a possible route for other TADs, such as 
African swine fever virus (ASFV) and PRRSV (Bowman, Krogwold, Price, Davis, & Moeller, 
2015).  
 1.3 Virus survival  
The concept of virus transmission through animal feeds and feed surfaces has been associated 
with emerging and endemic porcine pathogens in the U.S. and increased concerns associated 
with the risk of introduction or re-introduction and transmission of foreign animal diseases to the 
U.S. Mitigating the risk of pathogen introduction and transmission through contaminated animal 
feed and feed ingredients is a primary goal. To further define risk, studies have been conducted 
to demonstrate the ability of major transboundary swine viral pathogens to survive in feed when 
subjected to different environmental conditions such as temperature and humidity (S. Dee et al. 
2015, 2016) and trans-oceanic shipping models such as trans-Pacific and trans-Atlantic shipping 
models have been used to demonstrate a survivability of important viruses in swine feed 
ingredients that are frequently imported to the U.S. (S. A. Dee et al. 2018; Stoian et al. 2020). 
These models simulated shipping environmental conditions and timelines. Specifically, the trans-
Pacific model represents the transportation of swine feed ingredients from China to the U.S., 
including the simulated contamination of feed ingredients in Beijing, China (S. A. Dee et al. 
2018). The trans-Atlantic transportation model represents feed ingredients imported from 
Europe, specifically from Poland to the U.S. (S. A. Dee et al. 2018).Overall, the model 
demonstrated that the survival was dependent on virus and ingredient combinations (i.e., certain 
ingredients promoted the stability of several diverse viruses). Specifically, SVA was shown to be 
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highly stable across feed ingredients, surviving in 11 of 12 feeds or feed ingredients across the 
37-day trans-Pacific model. PRRSV was demonstrated to be less stable, surviving in only 2 
ingredients after 37 days. ASFV was also shown to be highly stable with infectious virus being 
detected in 9 of 12 ingredients after 30 days (Niederwerder et al. 2019). 
These viruses survived in specific feed ingredients such as conventional soybean meal, lysine 
hydrochloride, choline chloride, vitamin D and pork sausage casings. Survival of viruses 
depends on their structural properties and the specific feed matrices (S. A. Dee et al., 2018). 
Another study done by (Trudeau et al., 2017) showed that soybean meal preserved PEDV viral 
infectivity with titers of 0.83 log TCID50/ml compared to other animal feed and animal by-
products that that had titers of 0.50 log TCID50/ml when incubated for 56-day. In a recent 
review, the impact of feed manufacturing, supply environment, and transport systems were 
highlighted as additional contributors to virus transmission (Jones et al. 2019). Contaminated 
surfaces and equipment at feed manufacturing facilities can play a role in the dissemination of 
viral pathogens following production of contaminated feed and cross-contamination of 
equipment (Huss et al., 2017).  
Recent studies confirmed isolation of mammalian Ortho reovirus in porcine by-product, ring-
dried swine blood meal (RDSB) and pig feces in the U.S. (Narayanappa et al., 2015). SVA was 
recently isolated in swine feed ingredients in Brazil and was associated with a vesicular disease 
outbreak in commercial swine (Leme, Miyabe, Dall Agnol, Alfieri, & Alfieri, 2019).  
 1.3.1 Porcine reproductive and respiratory syndrome virus (PRRSV) 
Porcine reproductive and respiratory syndrome virus is a small, single-stranded, positive sense 
enveloped RNA virus, belonging to the family Arteriviridae and the order Nidovirales (Rossow 
1998). The genome of the virus is about 15kb in length with 11 open reading frames and 2 
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untranslated regions at the 3’ and 5’ ends (Han, Xu, and Wang 2019). PRRSV is relatively 
unstable in the environment and generally susceptible to most disinfectants. This virus survived 
in 2/12 (17%) of the feed ingredients tested in a trans-Pacific shipping model study (S. A. Dee et 
al. 2018). PRRSV is the causative agent of porcine reproductive and respiratory syndrome, 
which can cause disease in all age groups of pigs, including disease of significant economic 
importance to the U.S. with costs estimated at approximately $1.8 million per day (Holtkamp et 
al. 2012).  
 1.3.2 Seneca virus A (SVA) 
SVA is a small, single stranded RNA virus that is non-enveloped, belonging to the family 
Picornaviridae similar to other important virus causing vesicular diseases, such as FMD (Raquel 
A. Leme, Alfieri, and Alfieri 2017; Segalés et al. 2017). SVA is the only member of the genus 
Senecavirus. SVA was initially identified as a cell culture contaminant in 2002. In 2015, SVA 
was identified as a causative agent of vesicular disease in U.S. swine (Joshi, Fernandes, et al. 
2016; Joshi, Mohr, et al. 2016). Although pigs are identified as the natural hosts, antibodies to 
the virus have also been isolated from cattle and mice (Joshi, Mohr, et al. 2016). 
SVA is considered an emerging virus due to a recent increase in cases and distribution of the 
virus (Segalés et al. 2017). Importantly, clinical signs of SVA are indistinguishable from clinical 
signs of other important swine vesicular diseases. SVA is stable in the environment and recent 
studies highlighted the stability of the virus in animal feed, that may contribute to virus 
introduction and spread (S. A. Dee et al. 2018; Joshi, Mohr, et al. 2016; Raquel Arruda Leme et 
al. 2019) 
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1.4 Feed mitigation strategies  
Contaminated animal feed and/or feed ingredients have been recognized as a potential source of 
virus introduction and spread. To mitigate this risk, various mechanisms to inactivate viruses or 
reduce virus titers in feed have been proposed. Point-in-time mitigation methods such as heat 
inactivation and irradiation reduce or eliminate the quantity of infectious virus, however, they are 
prone to cross-contamination (Gebhardt et al. 2018). Chemical feed additives such as medium-
chain fatty acids (MCFA), formaldehyde-based additives, essential oils and dietary acidifiers 
have also been proposed as potential mitigation strategies (Cochrane et al. 2016; S. Dee et al. 
2016; Gebhardt et al. 2018). Feed additives associated with antiviral properties may have the 
advantage of residual duration of activity that controls cross-contamination (Gebhardt et al. 
2018).   
 1.4.1 Medium chain fatty acids (MCFA) 
MCFA are comprised of carbon atoms that are 6 to 12 long. They have been used as 
antimicrobials and have also shown an ability to promote growth when included in animal feed 
(Hanczakowska 2017; Takeuchi, Sekine, and Aoyama 2008). A recent study has shown the 
effect of MCFA are concentration dependent with higher concentrations having more effect on 
viral membranes than lower concentrations (Cochrane, Dritz, et al. 2016; Thormar et al. 1987). 
MCFA appear to have increased efficacy at a lower pH around 4.2 than at a neutral or high pH 
(Thormar et al. 1987). Capric acid (10:0) and lauric acid (12:0) have been shown to have high 
viricidal activity against Herpes Simplex Virus (HSV) and Visna Virus (VV), when used at a low 
pH (Thormar et al. 1987; Welsh, Skurrie, and May’ 1978). Increasing the contact time between 
MCFA and each virus increased efficacy with the higher the contact time translating to increased 
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virucidal effect (Hilmarsson et al.2006). The study by (Hilmarsson et al., 2006) on Visna Virus 
showed that virus titers were reduced to undetectable levels, a reduction of 4.5 log10 after 
exposure to lauric acid. This study also showed that lauric acid (12:0) had a greater effect on the 
virus compared to capric acid (10:0) which had no viricidal effects at a similar concentration. 
Lauric acid appears to inhibit the titer of Juvin Virus by reducing virus replication (Bartolotta et 
al., 2001). MCFA reduced the quantity of detectable PEDV RNA and render inactive  PEDV in 
swine bioassay in feed trial (Cochrane, Saensukjaroenphon, et al. 2016; S. Dee et al. 2016; 
Gebhardt et al. 2018). 
 1.4.2. Formaldehyde 
Formaldehyde based feed additives have been manufactured with the goal of pathogen reduction 
in feed. An example of one formaldehyde-based feed additive is Sal CURB® (Kemin Industries, 
Des Moines, IA, USA), which is 37% formaldehyde with a combination of organic acids and 
their salts (propionic acid and its salt, formic acid and its salts, sorbic acid, phosphoric acid). 
This product is approved by FDA to control Salmonella contamination in poultry and swine feed 
for up to 21days in feeds or feed ingredients (S. Dee et al. 2015, 2016).  
A recent study showed that Sal CURB® rendered some enveloped viruses such as coronavirus 
inactive (S. Dee et al. 2015, 2016). Although there is no clear mechanism of its action, it may 
cause cross-linking of proteins or nucleic acid, denaturation of viral cell membrane or lipoprotein 
membrane by alkylation (Möller et al. 2015; Wilton et al. 2014). Sal CURB® was shown to 
reduce PEDV infection in naïve piglets (S. Dee et al. 2014). However, Sal CURB® is not 
approved by the FDA as a means of PEDV mitigation. Formaldehyde-based products have been 
used as antimicrobial compound in poultry feed (Ricke, Richardson, and Dittoe 2019; Wales, 
Allen, and Davies 2010). 
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MCFA AND FORMALDEHYDE BASED FEED ADDITIVES: PROPOSED 
MECHANISMS OF ACTION AND EFFECT ON VIRUSES 
CHEMICAL/PRODUCT PROPOSED MECHANISM 
OF ACTION  
EFFECTS ON VIRUSES  
MCFA  Penetrates the viral envelope 
by hydrophobic effects and 
increase permeability to small 
molecules (Hilmarsson et al., 
2006)  that causes leakage 
through the viral envelope.  
At high concentrations, can 
cause disintegration of the 
viral envelope and viral 
particle (Thormar et al., 
1987). 
Effective against enveloped 
viruses such as vesicular 
stomatitis virus (VSV), 
Herpes simplex virus type 1 
(HSV-1) and visna virus 
(VV) (Thormar et al.,1987). 
 
Lentivirus related to HIV 
(Hilmarsson et al., 2006), 
Herpes simplex virus type 
1and 2 (Hilmarsson et 
al.,2006) 
Juvin virus (Bartolotta et al., 
2001). 
PEDV (S. Dee et al. 2015, 
2016) 
 
 
FORMALDEHYDE  Interacts with virus proteins 
and nucleic acid, can cause 
denaturation of microbial 
protein and acts on nucleic 
acid by alkylation 
(Maris,1995). 
Effective against enveloped 
viruses-such as PEDV and 
Turkey coronavirus (TCoV) 
(S. Dee et al. 2015, 2016) 
Poliovirus (Wilton et al.2014) 
 
 
Table 1: The proposed mechanism of MCFAs and formaldehyde and their effects on 
example viruses that are rendered inactive by the mitigants. 
 
 1.4.3 Advantages and disadvantages of chemical feed additives  
MCFA have been added to nursery diets to replace in-feed antimicrobials for reducing pathogens 
and improving pig performance with no significant effect on the gut microbiome (Gebhardt, 
Thomson, and Woodworth 2017). One study suggested that MCFA can be more easily digested 
than other sources of lipids and may reduce the accumulation of body fat (Takeuchi et al.2008). 
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Several studies have been performed on MCFA to demonstrate antiviral activity against many 
human enveloped viruses (Hilmarsson et al.,2006). MCFAs have been used as a blend of caproic, 
caprylic and capric acids, at a 1:1:1 ratio in feed studies (Cochrane, Saensukjaroenphon, et al. 
2016; Jordan T. Gebhardt et al. 2018), where 2 inclusion levels have showed efficacy against 
PEDV. Medium-chain triglyceride (MCT) added in weanling pigs diet improved average daily 
gain and digestibility during the first 2 weeks post-weaning (Lai, Yen, Lin, & Chiang, 2014). 
Lauric acid is a medium-chain fatty acid with the additional benefit of being formed into mono-
Laurin in the human or animal body (Hanczakowska, 2017). Mono-Laurin is the antiviral, 
antibacterial and antiprotozoal monoglyceride that has demonstrated effects on enveloped viruses 
such as HIV, herpesvirus, cytomegalovirus, and influenza virus (Hanczakowska, 2017).  
Formaldehyde based feed additives or 10% medium-chain fatty acid (MCFA) treatment of rice 
hulls reduced the quantity of detectable PEDV RNA compared to untreated rice hulls. 
Subsequently, the chemically treated feed was demonstrated to be non-infectious (Gebhardt et 
al., 2018). Formaldehyde has been used as a broad-spectrum antimicrobial in poultry and swine 
farms to reduce microbial contamination (Ricke, Richardson, and Dittoe 2019; Wales, Allen, and 
Davies 2010).  (Campbell et al. 2018) suggested that formaldehyde added into pig feed did not 
reduce pig growth performance and pigs were fed with formaldehyde treated spray dried porcine 
plasma showed increase in growth rate compared to the pigs in control group. In human 
medicine, there have been reports that MCFA has an ability to increase satiety and reduce feed 
intake over time (Takeuchi, Sekine, and Aoyama 2008) Thus, MCFA have been used to prevent 
and/or treat obesity (Coleman et al., 2016).Formaldehyde can be highly irritating and is a toxic 
agent to both humans and animals when inhaled or via direct contact (Watt 1912). Formaldehyde 
has also been described as a carcinogenic agent to humans; however, 0.1% of formaldehyde 
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included in animal feed is considered to have minimal effect in both animals and humans 
(Swenberg et al. 2013), However, because of feed safety and biosecurity, proper handling of 
treated feed is highly recommended. It also suggested that treatment of feed with 37% 
formaldehyde (Sal CURB®) reduced pig growth rate (Campbell, 2018b). Formaldehyde based 
feed additives may hinder protein availability in animal feed due to the ability to denature and 
cause cross-linking of protein (Devi, Balasubramanian, Kim, & Kim, 2016). 
 
Figure 1: Schematic illustration of mitigation strategies for potentially contaminated 
imported feed and/or feed ingredients to the U.S. 
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Chapter 2 - Inactivation of Seneca virus A using medium-chain fatty 
acids and formaldehyde-based feed additives in cell culture 
 2.0 Introduction 
U.S. swine endemic viruses  
Endemic swine viruses for the purposes of this work are considered those viruses that are 
currently circulating in the U.S. Although endemic viruses are present within the country, there 
are substantial differences on the distribution and prevalence of each virus from herd to herd, 
county to county, and state to state. There are several factors that may contribute to the 
prevalence, introduction and re-introduction, transmission or spread of these viruses. Based on 
the recent finding that many viruses can survive in animal feed and or feed ingredients that are 
widely distributed throughout U.S. swine herds, this work has focused on investigating 
mitigation strategies for two important endemic diseases of swine to the U.S., including SVA 
and PRRSV. SVA and PRRSV are both currently circulating swine viruses that have potential to 
impact the health, welfare, and economy of the swine industry. Both viruses were shown to 
survive in animal feed and/or feed ingredients subjected to transoceanic conditions (S. A. Dee et 
al., 2018), with SVA surviving in 11 of the 12 ingredients tested and PRRSV surviving in 2 of 
the 12 ingredients tested. As both endemic diseases and foreign viral diseases of swine are of 
great importance to sustainable pork production and markets within and outside the country, this 
calls for significant investigation and control strategies to mitigate the risk (Jones, Woodworth, 
Dritz, & Paulk, 2019). 
 2.1 Seneca virus A  
SVA is a small, single-stranded, positive sense, non-enveloped RNA virus belonging to the 
Picornaviridae family and the only member of the genus Senecavirus (Joshi, Mohr, et al. 
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2016).The virus is also known as Seneca Valley virus (SVV). The genome of SVA is 
approximately 7.2 kb and the virus has an internal ribosomal entry site that allows translation in 
the cap-independent manor (Segalés et al. 2017).  
 
 
Figure 2: Genome and structure of Seneca virus A. 
 
SVA was incidentally discovered as a cell culture contaminant during cultivation of PER.C6 
cells (fetal retinoblastoma cell line) (Burke, 2016). The source of the virus was associated with 
the use of animal by-products such as serum or trypsin of porcine origin (Burke, 2016).  
Following sequence and serological analysis, retrospective studies between 1988 and 2005 
identified 6 closely related picorna-like viruses isolated in different regions of the U.S. that 
seemed to cause various clinical signs. SVA was one of these viruses and this showed that the 
virus has been circulating in U.S. pigs for a long time before it was officially identified (Zhang et 
al., 2018). 
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Figure 3: World distribution of SVA. Countries marked in blue have detected SVA cases in 
pigs. 
 
2.2 Why is SVA important  
SVA is a causative agent of porcine vesicular disease in pigs, initially identified as an idiopathic 
vesicular disease (IDV), which has a wide geographic distribution (Segalés et al. 2017). The 
disease is characterized by infrequent cases of vesicles and erosions on the skin, snout, oral 
cavity, and coronary bands (Raquel A. Leme, Alfieri, and Alfieri 2017b). Clinical signs of the 
disease are indistinguishable from that of other (foreign) animal vesicular disease causative 
agents. The virus is of less economic significance, but due to clinical signs resembling that of 
devastating vesicular foreign animal diseases, such as foot and mouth disease, swine vesicular 
disease, vesicular stomatitis, and vesicular exanthema of swine, diagnostic testing is always 
required to rule out important foreign animal vesicular diseases. SVA has been reported in seven 
other countries (Leme, Alfieri, and Alfieri 2017). 
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There is no commercially available vaccine for SVA. Various research has been done to describe 
the virus along with the establishment of rapid diagnostic methods (Zhang et al., 2018) . SVA is 
considered to be an emerging or re-emerging virus in different geographical locations due to the 
increased incidence of the disease (Segalés et al. 2017).This highlights the ability of the virus to 
emerge and re-emerge in new geographical locations and ability to cause novel conditions in pigs 
around the world. SVA has been used as an important surrogate for foot-and-mouth disease 
virus, a foreign animal disease pathogen in the U.S., which requires biosafety-level 4 (BSL-4) 
laboratory containment conditions. Both SVA and FMDV are in the Picornaviridae family and 
have similarity in genetic and physiochemical properties (S. A. Dee et al., 2018).  
 
 2.3 Materials and Methods  
1. Mitigants and effect on cells 
Mitigants tested in this experiment included MCFAs, which consisted of a blend of capra fatty 
acids (C6: Caproic acid, C8: Caprylic acid and C10: Capric acid at a ratio of 1:1:1) and 
formaldehyde-based liquid (FORMALD, SalCURB®, Kemin Industries, 37% formaldehyde with 
organic acids and their salts). Cells utilized in this experiment were PK -15 (porcine kidney cells, 
PK15, PK15; ATCC® CCL33TM). To determine if the mitigants induced a cytopathic effect on 
PK-15 cells, 100 µl of a 5% concentration of MCFAs or FORMALD was added onto confluent 
monolayer of PK-15 cells. Cells with Minimum essential media (MEM) only was used as a 
negative control where 100 µl of MEM was added onto confluent monolayers of PK-15 cells 
followed by three days incubation at 37°C. Mitigants were discarded after three days and cells 
were washed three times using 100 µl of PBS and viewed under fluorescent microscope.  
2. Cells and virus   
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PK-15 cells in DMEM media with 7% heat-inactivated fetal bovine serum (FBS), streptomycin, 
penicillin and antimycotics were seeded in a 96-well plate, incubated in a 5% CO2/95% air 
atmosphere at 37°C. Cells were grown to 95-100% confluence. The Seneca virus A isolate 
(SVA; GenBank accession No. KX349734) (Chen et al. 2016) had a green fluorescent tag and 
was kindly obtained from Dr. Ying Fang at the University of Illinois.  
3. Virus titration  
Confluent PK-15 cells in a 96-well plate were utilized to titer the initial virus stock. Serial ten-
fold dilutions were performed in MEM media and each dilution was inoculated in triplicate onto 
confluent cells. Cells were incubated at 37°C for 2-3 days. Plates were examined under a 
fluorescent microscope every 24 hours. The endpoint dilution method was used to determine the 
virus titers calculated using the method of Reed and Muench (REED and MUENCH 1938) Initial 
virus stocks had titers of 108 - 109 TCID50/ml. 
4. Mitigants 
Concentrations of each mitigant were created between 10% and 0.1% in MEM media.  
5. Assay of antiviral activity  
A 20% solution of mitigant was prepared from the original stock solution and 100 µl of 20% 
mitigant solution was mixed with 100 µl of SVA (106 TCID50/ml), resulting in a final 
concentration of mitigant of 10%. This was repeated for other mitigant concentrations tested 
between 0.1% and 5%. Positive control included 100 µl of virus and 100 µl of MEM 
maintenance media in place of the mitigant. Negative controls included media alone with cells 
(no virus or mitigants). The 96-well plate was then used to perform 1:10 serial dilutions of the 
mitigants/SVA mixtures of the virus described above. Plates were incubated for 30 minutes at 
room temperature prior to being plated onto a separate 96-well plate previously seeded with PK-
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15 cells. The media on cells was discarded prior to transfer of 100 µl from each well of the 
dilution plate to the corresponding well of the plate containing PK-15 cells. Cells were 95-100% 
confluent at the time of infection. Plates were incubated for 48 hours at 37±2°C with 5% CO2. 
After 24 hours and again at the end of the 48-hour incubation period, we inspected all wells 
under fluorescent microscopy. We categorized each well as either positive or negative based on 
the presence or absence of virally infected cells. Endpoint titers were calculated as described 
above and mitigant treated samples were compared to positive controls. 
 2.4 Results  
Mitigants had no significant cytopathic effect when inoculated onto the PK-15 cells after three 
days incubation period.           
    
Figure 4: PK-15 cell line treated with MCFAs (left) and FORMALD (right) after three 
days incubation period. Magnification of 200x. 
 
Assay of antiviral activity: 
Exposure to FORMALD demonstrated efficacy for reducing SVA titers in the cell culture model. 
Specifically, SVA was undetectable under fluorescent microscope when a high concentration 
(5%) of FORMALD was used. No significant reduction of SVA titers were noted after exposure 
to up to 5% MCFA.   
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Figure 5: PK-15 cells after being challenged with virus-mitigant mixture, SVA-MCFA (left) 
and SVA-FORMALD (right). Magnification of 200x. 
 
Dose response inactivation. 
Inactivation of SVA using FORMALD: 
FORMALD showed efficacy at reducing SVA titers. Concentrations higher than 0.6% caused 
inactivation of SVA titer to below the level of detection on cell culture while concentrations 
between 0.15%-0.3% reduced SVA titers by approximately 1 log (3.16x106 TCID50/ml to 
3.16x105 TCID50/ml). The lowest concentration of FORMALD tested was 0.01875% and no 
significant reduction of SVA titer was noted as the titer was similar to that of the positive control 
virus at 3.16x106 TCID50/ml. 
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Figure 6: Dose response inactivation curve of FORMALD against SVA. 
 
Inactivation of SVA with MCFA:  
Exposure to MCFAs caused no significant reduction of SVA titer even at the highest 
concentration of 5% up to 30 minutes incubation period. 
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Figure 7: Dose response inactivation curve of MCFA against SVA. Data is shown for titers 
after no incubation period.  
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Figure 8: Dose response inactivation curve of MCFA against SVA. Data is shown for titers 
after 30 minutes of incubation.  
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The incubation period was later increased to 45 minutes where 5% concentration reduced the 
SVA titer by approximately 1log.  
 
Figure 9: Dose response inactivation curve of MCFA against SVA. Data is shown for titers 
after 45 minutes of incubation. 
  
 2.5 Discussion  
FORMALD was effective toward SVA with concentrations greater than 0.6% reducing the virus 
titer to below that which can be detected in cell culture. The efficacy may be due to the ability of 
formaldehyde to denature the virus particle or viral proteins by alkylation. However, no 
significant reduction of SVA titers were noted after exposure to MCFA up to 5% at 30-minutes 
incubation period. SVA titer was reduced by approximately 1log after the incubation period of 
45-minutes at 5% MCFA concentration. Stability of SVA to MCFA may be due to lack of the 
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viral envelope as MCFAs is considered to have a proposed mechanism of action on viral 
envelopes.  
  
25 
Chapter 3 - Inactivation of porcine reproductive and respiratory 
syndrome virus (PRRSV) using medium chain fatty acids (MCFAs) 
and Formaldehyde based feed additives in cell culture 
 3.0 Introduction 
 3.1 Porcine reproductive and respiratory syndrome virus  
PRRSV is a single stranded, positive sense enveloped RNA virus. The virus belongs to the 
family Arteriviridae similar to equine arteritis virus, mouse lactate dehydrogenase-elevating 
virus, and simian hemorrhagic fever virus within the order Nidovirales (Dokland 2010). 
The viral nucleocapsid is surrounded by envelope proteins, glycoproteins and membrane proteins 
to form virion particle (Nelsen, Murtaugh, and Faaberg 1999).The genome has 11 open reading 
frames (ORF) that code for both structural and non-structural proteins (Charerntantanakul 2012). 
ORF 1a and 1b code for non-structural protein pp1a and pp1b; these are polyproteins that are 
later processed into 14 peptides (Rossow 1998). ORF 2-11 carries information for structural 
proteins such as glycoproteins (2-5) translated from ORF 2-5 (Rossow 1998).The rest of the 
ORFs encode for three un-glycosylated membrane proteins (E, ORF5a, and M) (Nelsen, 
Murtaugh, and Faaberg 1999; Snijder, Kikkert, and Fang 2013). A nucleocapsid protein (N) of 
GP 5 is most abundant and the primary contributor to host immune response (Rossow 1998).  
PRRSV is characterized into two genotypes, including the European and North American 
genotype, also named as genotype one and type two, respectively (Gauger et al. 2012; Rossow 
1998; Snijder, Kikkert, and Fang 2013). Both genotypes are found worldwide in countries where 
PRRSV is endemic. Both genotypes cause similar clinical signs in swine but have significant 
variability in their nucleotide sequence, with only 60-75% nucleotide similarity (Pei et al. 2009). 
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Pigs are the natural host of PRRSV. The virus particle has tropism to immune cells like those of 
the monocytic lineage (Loving et al. 2015). Porcine alveolar macrophages are known to be the 
primary replication site for the virus; however, replication also occurs in other immune cells like 
dendritic cells (Loving et al. 2015). Other cell lines such as MARC-145 cells and other related 
cell lines derived from African green monkey kidney cells are permissive in vitro (Lunney et al. 
2016a). Different receptors for the virus have been described with CD163 being the primary 
receptor (Jay G Calvert et al. 2007). Viral glycoproteins GP2a and GP4 facilitate virus 
attachment (Dokland 2010). Virus enters the cells through clathrin-mediated endocytosis; 
endosome acidification after fusion facilitates genome release into the host cell cytosol followed 
by genome replication in the cytoplasm (Lunney et al. 2016a).  
Viral infection can be acute, sub-acute or persistent (Lunney et al. 2016a). Replication of the 
virus in porcine alveolar macrophages and dendritic cells can lead to lung infection (Lunney et 
al. 2016b; Rossow 1998). Blood of infected pigs can be PRRSV positive 6-12 days after 
infection (Lunney et al. 2016b; Rossow 1998). Persistent infection occurs when virus is localized 
to the tonsil and lymph nodes (Charerntantanakul 2012). The last stage of infection occurs when 
virus replication ceases, following gradual declines (Charerntantanakul 2012).  The severity of 
disease depends on herd immunity and virus strain (Mondaca-Fernández et al. 2007; Nelsen, 
Murtaugh, and Faaberg 1999).  
PRRSV can be transmitted both directly and indirectly. Direct transmission, which is very 
efficient, can be horizontal or vertical within infected herds (Charerntantanakul 2012). Infected 
pregnant sows can be the source of virus to piglets as PRRSV is capable of crossing the placenta 
during the third trimester (Larochelle and Magar 1997; Lunney et al. 2016a). 
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Indirect transmission involves contaminated fomites, including transport vehicles, needles, and 
personnel (Charerntantanakul 2012). PRRSV infection stimulates antibody production by day 7 
post infection; however, this antibody does not neutralize the virus and does not provide 
protection (Loving et al. 2015; Pei et al. 2009). Neutralizing antibodies may be produced by day 
28 post infection, however, they still do not provide complete protection (Loving et al. 2015). 
The virus has been mentioned to suppress innate immune responses (Ansari et al. 2006). 
Multiple vaccinations or repeated infection may produce neutralizing antibodies that are 
protective. Serum from infected animals when transferred to naïve pigs has been shown to 
passively protect the naïve animal (Larochelle and Magar 1997). Over a time, various virus 
strains have evolved and caused considerable loses as well as increased severity of disease. The 
virus is prone to mutation and recombination, leading to the development of different strains (J. 
G. Calvert et al. 2007). In Asia, the highly pathogenic PRRSV strains cause over 20% mortality, 
associated with high fever and respiratory syndrome (Charerntantanakul 2012). Both the Lena 
strain and the highly virulent 184 strain have caused severe clinical signs to pigs in Eastern 
Europe and north-central America, respectively (Charerntantanakul 2012). PRRSV has been 
isolated as a cofactor in porcine respiratory disease complex (PRDC) and is the main cause of 
respiratory infection in most cases (Gauger et al. 2012). 
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Figure 10: The genome and structure of PRRSV. 
 
Porcine reproductive and respiratory syndrome virus (PRRSV) affects all age groups 
(Rossow1998). Reproductive impairment or failure is typically noted by increases in the number 
of stillborn piglets, mummified fetuses, premature farrowing, and weak-born pigs (Larochelle 
and Magar 1997). Abortions typically occur in less than 10% in the endemic herd (Rossow, 
1998). The respiratory syndrome is seen more often in young growing pigs but can also occur in 
naïve finishing pigs and breeding stock; infection in these age groups can last for up to four 
months (Mondaca-Fernández et al. 2007; Rossow 1998). PRRSV can reduce weight gain by 85% 
and cause mortality up to 10%-25% in the infected farm (Rossow 1998). Although reported 
initially in only a few countries in the late 1980s, PRRS now occurs worldwide in most major 
swine-raising countries (Charerntantanakul 2012). PRRS is prevalent in the United States and 
exists both in epidemic and endemic forms. Various control strategies have been developed and 
established; however, there is no clearly successful control strategy to date (Lunney et al. 2016a).  
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This is likely due to viral mutation and recombination that leads to highly pathogenic, highly 
virulent, or new viruses that may reduce the efficacy of available vaccines. (Gauger, Faaberg, 
Guo, Kappes, & Opriessnig, 2012). 
 
Figure 11: World distribution of PRRSV. Countries marked in blue have detected PRRSV 
cases in pigs. 
 
 3.2 Why is PRRSV important  
PRRS causes a tremendous economic loss in the swine industry worldwide. Losses are primarily 
associated with reproductive failure and mortality of young piglets due to respiratory problems as 
well as reduced growth (Nelsen, Murtaugh, & Faaberg, 1999). In the United States, PRRSV results 
in losses of $1.8 million per day, equivalent to $664 million per year (Holtkamp et al., 
2012).Veterinary and biosecurity expenses can cost up to $140.11 million and $191.86 annually, 
respectively, while other related costs can reach $145 million (Holtkamp et al., 2012). 
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Individual cost Total cost 
Breeding herds $302.06 million $664 million annually 
($1.8 million per day). 
 (Holtkamp et al., 2012) Growing pig herd $361.8 million 
Veterinary cost $140.11 million $477.79 million 
(Holtkamp et al., 2012) 
Biosecurity   $191.86 million 
Other outbreak-related costs $145.82 million 
 
Table 2: Estimated Annual Cost of PRRS in the U.S. 
 
There is a continual threat from the potential emergence of increasingly divergent and often 
virulent PRRSV strains (Han et al. 2019) One example is the disease outbreak in China in 2006, 
where infected pigs developed various clinical signs that led to an increase in the death of pigs of 
all age groups (Han et al. 2019). PRRSV was identified to be the dominant virus by 40% in the 
outbreak and the virus was rapidly transmitted between herds in various provinces (Tong et al. 
2007). The virus was identified as highly pathogenic and associated with high mortality between 
20%-100% and a morbidity rate between 50%-100%  (Tong et al. 2007). Glycoprotein 5 (GP5) 
was identified to have mutations in the highly pathogenic PRRSV virus and other strains 
(Nelsen, Murtaugh, and Faaberg 1999). Mutation and recombination of PRRSV contributed to 
emergence of two novel stains recently isolated (ZJnb16-2, SDbz16-2) in China that seemed to 
not be protected by available vaccines (Han, Xu, and Wang., 2019). The tendency for viral 
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mutation makes the development of accurate diagnostic tools and a universal vaccine against 
PRRSV challenging.  
The possibility of developing endemic herd infections after an outbreak and the ability of the 
virus to persist for up to 200 days in carrier pigs contributes to the introduction and maintenance 
of the virus to the pig population (Charerntantanakul 2012). The virus can be introduced into the 
herd through direct contact of infected pigs to healthy pigs, as well as various fomites and 
potentially aerosol transmission. Infected pregnant sows can transmit viruses vertically to piglets 
and lead to the development of congenital PRRS infection, while shedding of viruses from 
piglets and sows can lead to infection of other pigs (Charerntantanakul 2012; Dokland 2010b). 
Infected boars contribute to virus transmission by shedding the virus in semen for up to three-
months post-infection and infect sows through natural breeding or artificial insemination 
(Dokland 2010a; Rossow 1998; Song, Moon, and Kang 2015). 
 
 3.3 Materials and Methods  
1. Determining effects of mitigants on cells  
Mitigants tested in this experiment included MCFAs, which consisted of a blend of capra fatty 
acids (C6: Caproic acid, C8: Caprylic acid and C10: Capric acid at a ratio of 1:1:1) and 
formaldehyde-based liquid (FORMALD, SalCURB®, Kemin Industries, 37% formaldehyde with 
organic acids and their salts). Cells utilized in this experiment were MARC-145 (African green 
monkey kidney cells). To determine if the mitigants induced a cytopathic effect on MARC-145 
cells, 100 µl of a 5% concentration of MCFAs or FORMALD was added onto confluent 
monolayers of MARC-145 cells. Cells with minimum essential media (MEM) only was used as a 
negative control where 100 µl of MEM was added onto confluent monolayers of MARC-145 
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cells followed by three days incubation at 37°C. Mitigants were discarded after three days and 
cells were washed three times using 100 µl of PBS and viewed under a fluorescent microscope.  
2. Cells and virus   
MARC-145 cells in DMEM media with 7% heat-inactivated fetal bovine serum (FBS), 
streptomycin and penicillin as well as antimycotics were seeded in a 96-well plate, incubated in a 
5% CO2/95 % air atmosphere at 37°C. Cells were grown to 95-100% confluence. The PRRSV 
isolate used was a type 2 was derived from an infectious clone of P129 strain (Pei et al. 2009) 
and had a green fluorescent tag.   
3. Virus titration  
Confluent MARC-145 cells in a 96-well plate were utilized to titer the initial virus stock. Serial 
ten-fold dilutions were performed in MEM media and each dilution was inoculated in triplicate 
onto confluent cells. Cells were incubated at 37°C for 2-3 days. Plates were examined under a 
fluorescent microscope every 24 hours. The endpoint dilution method was used to determine the 
virus titers calculated using the method of Reed and Muench (REED and MUENCH 1938). The 
initial virus stocks had titers of 106 TCID50/ml. 
4. Mitigants 
Concentrations of each mitigant were created between 10% and 0.1% in MEM media.  
5. Assay of antiviral activity  
A 20% solution of mitigant was prepared from the original stock solution and 100 µl of 20% 
mitigant solution was mixed with 100 µl of PRRSV (106 TCID50/ml), resulting in a final 
concentration of 10% mitigant. This was repeated for all other mitigant concentrations tested 
between 0.1% and 5%. Positive control included 100 µl of virus and 100 µl of MEM 
maintenance media in place of the mitigant. Negative controls included media alone with cells 
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(no virus or mitigants). The 96-well plate was then used to perform 1:10 serial dilutions of the 
mitigants/PRRSV mixtures described above. Plates were incubated for 30 minutes at room 
temperature prior to being plated onto a separate 96-well plate previously seeded with MARC-
145 cells. The media on cells was discarded prior to transfer of 100 µl from each well of the 
dilution plate to the corresponding well of the plate containing MARC -145 cells. Cells were 95-
100% confluent at the time of infection. Plates were incubated for 48 hours at 37±2°C with 5% 
CO2. After 24 hours and again at the end of the 48-hour incubation period, we inspected all wells 
under fluorescent microscopy. We categorized each well as either positive or negative based on 
the presence or absence of virally infected cells. Endpoint titers were calculated as described 
above and mitigant treated samples were compared to positive controls. 
 
 3.4 Results 
Mitigants had no cytopathic effect when inoculated onto the MARC-145 cells, there were no 
significant changes on the cells compare to the normal monolayer of MARC-145 cells.  
    
Figure 12: MARC-145 cell line treated with MCFAs (left) and FORMALD (right) after 
three days incubation period. Magnification of 200x. 
 
Assay of antiviral activity: 
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Exposure to FORMALD and MCFAs demonstrated efficacy for reducing PRRSV titers in the 
cell culture model. Specifically, PRRSV was undetectable under fluorescent microscope when a 
high concentration (5%) of FORMALD and MCFA was used.  
. 
  
Figure 13: MARC 145 cells after being challenged with virus-mitigant mixture, PRRSV-
MCFA (left) and PRRSV-FORMALD (right). Magnification of 200x. 
 
Dose response inactivation. 
Inactivation of PRRSV with FORMALD 
FORMALD showed efficacy at reducing PRRSV titers. Concentrations higher than 0.15% 
caused inactivation of PRRSV titer to below the level of detection on cell culture while the 
concentration of 0.1% reduced PRRSV titers by approximately 2 logs (3.16x106 TCID50/ml to 
3.16x104 TCID50/ml). The lowest concentration of FORMALD tested was 0.0375% and no 
significant reduction of PRRSV titer was noted as the titer was similar to that of the positive 
control virus at 3.16x106 TCID50/ml. 
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Figure 14: Dose response inactivation curve of FORMALD against PRRSV  
 
Inactivation of PRRSV with MCFA 
MCFA showed efficacy at reducing PRRSV titers. Concentrations higher than 0.25% caused 
inactivation of PRRSV titer to below the level of detection on cell culture while concentration of 
0.2% reduced PRRSV titers by approximately 3 logs (3.16x106 TCID50/ml to 3.16x103 
TCID50/ml). The lowest concentration of MCFA tested was 0.1% and no significant reduction of 
PRRSV titer was noted.  
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Figure 15: Dose response inactivation curve of MCFAs against PRRSV. 
 
 3.5 Discussion  
The objectives of this study were to evaluate the efficacy of MCFAs and FORMALD in reducing 
the titer or inactivating PRRSV in a cell culture model and determining the dose response 
inactivation curve. To achieve these goals, various dilutions of FORMALD and MCFAs were 
prepared and used to assess efficacy in reducing or inactivating PRRSV. FORMALD showed 
efficacy by inactivating PRRSV at concentrations as low as 0.15%. The efficacy of FORMALD 
toward PRRSV may be due to denaturation of viral proteins caused by formaldehyde as the 
primary active ingredient, which is mentioned to have an antiviral ability to mitigate the risk of 
PEDV in animal feed and feed ingredients (Maris,1995). 
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On the other hand, MCFAs reduced PRRSV titer to below detectable levels after exposure to 
MCFA between 5% to 0.25% concentration. We hypothesize this may be due to the proposed 
mechanism of MCFAs to increase the permeability of the viral envelope and at high 
concentrations, it may cause disintegration of the viral envelope and viral particle (Thormar et 
al., 1987).  
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Chapter 4 - Animal feed trial 
 4.0 Introduction  
Contaminated complete feed has been implicated as one of the potential sources for animal 
disease spread within a country. Following an outbreak of PEDV in the U.S. in 2013, this risk 
was recognized as a potential contributor to virus transmission and rapid spread across pork 
producing states (S. Dee et al., 2014). Various studies have been done to show the possibility of 
other U.S. endemic viruses being spread through contaminated animal feed and/or feed 
ingredients, where certain viruses survived in specific feed ingredients (S. A. Dee et al., 2018). 
Among those, SVA was mentioned to be stable in most of the feed ingredients and PRRSV was 
less stable but still showed some degree of stability (S. A. Dee et al., 2018; Joshi et al., 2016; 
Stoian et al., 2020a). Having this background, it is important to consider risk mitigation 
strategies that will inactivate the viruses and hence reduce the chance of virus introduction/re-
introduction, transmission and spread from one place to another through contaminated animal 
feed (S. Dee et al., 2015; Gebhardt et al., 2019; Pasick et al., 2014). 
The objective of the current study was to investigate the stability of SVA in complete swine feed 
when subjected to MCFAs and FORMALD in a cell culture model. 
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4.1 Materials and Methods 
       1.  Cells and virus  
PK-15 cells in DMEM media with 7% heat-inactivated fetal bovine serum (FBS), streptomycin 
and penicillin and antimycotic were seeded onto 96-well plates and incubated in a 5% CO2/95% 
air atmosphere at 37°C. Cells were grown to 95-100% confluent. PK -15 cells were used for 
experiments with Seneca virus A (SVA; GenBank accession No. KX349734) (Chen et al. 2016) 
as described above.  
6. Virus titration  
Confluent PK-15 cells in 96-well plates with 180µl MEM media was inoculated with 20 µl of 
virus. Inoculation was done in triplicate, followed by 1:10 serial dilutions, and incubated at 37°C 
for two to three days. Plates were examined under a fluorescent microscope after 24 hours. 
The virus titers were determined by end-point dilution method using Reed and Muench (REED 
and MUENCH 1938). 
7. Feed preparation and inoculation  
Five grams of complete swine feed was added to 50ml conical tubes in duplicate. Two 
tubes were prepared per batch, including mitigant treated, positive controls and negative 
controls. All procedures were completed in a BSC to avoid cross-contamination. To prepare 
negative controls, 100µl of sterile PBS was added into 5g of feed in 50ml tubes and vortexed at 
the highest speed for 30 sec. For positive control, 100µl of virus (106TCID50/ml SVA) was added 
into 5g of feed in 50ml tubes and vortexed at the highest speed for 30 sec. For mitigant treated 
samples, 50µl (1% MCFAs) or 16.5µl (0.33% FORMALD) was added into 5g of feed in 50ml 
tubes, vortexed at the highest speed for 30 seconds, followed by inoculation of 100µl of virus 
(106TCID50/ml SVA) and vortexed for 5 seconds. Samples were vortexed for 10 seconds at the 
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highest speed after mock inoculation or inoculation. After vortexing, 15 ml of sterile PBS with 
antibiotics and anti‐mycotic were added to each sample for processing, vortexed for 10 seconds 
and centrifuged at 10,000 g for 5 min at 4°C. The supernatants were then aliquoted into cryovials 
and stored at −80°C. 
8. Virus isolation and titration 
For titration of feed supernatant samples, 2-fold serial dilutions of each sample were prepared in 
MEM in triplicate and plated onto confluent monolayers of PK-15 cells. After incubation at 37°C 
for 2 to 3 days, cells were examined under fluorescent microscope for evidence of infection and 
titers were calculated as described above.  
 
4.2 Results  
SVA remained viable in complete feed after treatment with MCFAs and FORMALD as there 
was no significant reduction of titer of mitigant treated samples. The titers were not significantly 
different from that of complete feed positive control after three days incubation period, as shown 
in table 9. No significant reduction in SVA titer was noted after exposure to mitigants in a 
complete feed model with no incubation time. 
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a) Complete feed-SVA: positive control.        b)  Complete feed: negative control. 
 
  
 
c) MCFA-complete feed treated PK-15 cells   d) FORMALD-complete feed treated PK-
15 cells  
Figure 16: Complete feed trial, the presence of green cells indicates infected cells by SVA. 
Images representative of A) the positive control is the result of complete feed spiked with SVA 
b) negative control, the mock inoculation of complete feed with sterile normal saline c) MCFA-
SVA treated feed with SVA d) FORMALD treated feed with SVA. Magnification of 200x. 
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Figure 17: Complete feed trial, dose response inactivation curve of SVA-complete feed-
mitigants and controls (positive control and negative control). 
 
 4.3 Conclusion 
Overall, these studies provide evidence suggesting that FORMALD and MCFAs may be used as 
potential feed additives to reduce the risk SVA and PRRSV transmission and dissemination in 
animal feed and feed ingredients. This data is supported by studies performed on a cell culture 
model which indicated the concentration necessary to reduce the virus titers and mitigate the risk 
of virus transmission through feed. The use of feed additives is a potential strategy to reduce the 
risk of endemic swine disease spread through feed and plays a role in the concept of feed 
biosecurity. Further studies should be performed in complete feed at various incubation times, 
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other feed ingredients, and in vivo experiments to confirm the efficacy of feed additives in 
reducing the risk of infection to pigs. This will further assess risk mitigation in control of 
emerging and re-emerging transboundary animal diseases in feed and/or feed ingredients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
 
Chapter 5 - References  
1. Dee, S. A., Bauermann, F. V., Niederwerder, M. C., Singrey, A., Clement, T., De Lima, M., 
Diel, D. G. (2018). Survival of viral pathogens in animal feed ingredients under 
transboundary shipping models. PLoS ONE, 13(3). 
https://doi.org/10.1371/journal.pone.0194509 
2. Dee, S., Clement, T., Schelkopf, A., Nerem, J., Knudsen, D., Christopher-Hennings, J., & 
Nelson, E. (2014). An evaluation of contaminated complete feed as a vehicle for porcine 
epidemic diarrhea virus infection of nai¨ve pigs following consumption via natural feeding 
behavior: Proof of concept. BMC Veterinary Research, 10(1), 1–9. 
https://doi.org/10.1186/s12917-014-0176-9 
3. Dee, S., Neill, C., Clement, T., Singrey, A., Christopher-Hennings, J., & Nelson, E. (2015). 
An evaluation of porcine epidemic diarrhea virus survival in individual feed ingredients in the 
presence or absence of a liquid antimicrobial. Porcine Health Management, 1. 
https://doi.org/10.1186/s40813-015-0003-0 
4. Devi, S. M., Balasubramanian, B., Kim, Y. M., & Kim, I. H. (2016). 287 Effects of Herbiotic 
FS Supplementation in weanling pigs. Journal of Animal Science, 94(suppl_2), 134–135. 
https://doi.org/10.2527/msasas2016-287 
5. Gebhardt, J. T., Cochrane, R. A., Woodworth, J. C., Jones, C. K., Niederwerder, M. C., 
Muckey, M. B., … Dritz, S. S. (2018). Evaluation of the effects of flushing feed manufacturing 
equipment with chemically treated rice hulls on porcine epidemic diarrhea virus cross-
contamination during feed manufacturing. Journal of Animal Science, 96(10), 4149–4158. 
https://doi.org/10.1093/jas/sky29 
6. Hanczakowska, E. (2017). The Use of Medium-Chain Fatty Acids in Piglet Feeding – A 
Review. Annals of Animal Science, 17(4), 967–977. https://doi.org/10.1515/aoas-2016-0099 
7. Lai, W. K., Yen, H. C., Lin, C. S., & Chiang, S. H. (2014). The effects of dietary medium-
chain triacylglycerols on growth performance and intestinal microflora in young pigs. Journal 
of Animal and Feed Sciences, 23(4), 331–336. https://doi.org/10.22358/jafs/65669/2014 
8. Schumacher, L. L., Woodworth, J. C., Jones, C. K., Chen, Q., Zhang, J., Gauger, P. C., … 
Dritz, S. S. (2016). Evaluation of the minimum infectious dose of porcine epidemic diarrhea 
45 
virus in virus-inoculated feed. American Journal of Veterinary Research, Vol. 77, pp. 1108–
1113. https://doi.org/10.2460/ajvr.77.10.1108 
9. Bowman, A. S., Krogwold, R. A., Price, T., Davis, M., & Moeller, S. J. (2015). Investigating 
the introduction of porcine epidemic diarrhea virus into an Ohio swine operation. BMC 
Veterinary Research, 11(1), 1–7. https://doi.org/10.1186/s12917-015-0348-2 
10. Huss, A. R., Schumacher, L. L., Cochrane, R. A., Poulsen, E., Bai, J., Woodworth, J. C., … 
Jones, C. K. (2017). Elimination of porcine epidemic diarrhea virus in an animal feed 
manufacturing facility. PLoS ONE, 12(1). https://doi.org/10.1371/journal.pone.0169612 
11. Lee, C. (2015, December 22). Porcine epidemic diarrhea virus: An emerging and re-
emerging epizootic swine virus. Virology Journal, Vol. 12. https://doi.org/10.1186/s12985-
015-0421-2 
12. Lowe, J., Gauger, P., Harmon, K., Zhang, J., Connor, J., Yeske, P., … Main, R. (2014). Role 
of transportation in the spread of porcine epidemic diarrhea virus infection, U.S. Emerging 
Infectious Diseases, 20(5), 872–874. https://doi.org/10.3201/eid2005.131628 
13. Niederwerder, M., & Hesse, D. (n.d.). Title: Comprehensive Literature Review on the current 
knowledge for Porcine Epidemic Diarrhea Virus and Porcine Deltacoronavirus-NPB #16-
266 Investigator. 
14. Opriessnig, T., Xiao, C. T., Gerber, P. F., Zhang, J., & Halbur, P. G. (2014). Porcine 
epidemic diarrhea virus RNA present in commercial spray-dried porcine plasma is not 
infectious to naïve pigs. PLoS ONE, 9(8). https://doi.org/10.1371/journal.pone.0104766 
15. Pasick, J., Berhane, Y., Ojkic, D., Maxie, G., Embury-Hyatt, C., Swekla, K., … 
Alexandersen, S. (2014). An investigation into the role of potentially contaminated feed as  
16. source of the first-detected outbreaks of porcine epidemic diarrhea in Canada. 
Transboundary and Emerging Diseases, 61(5), 397–410. https://doi.org/10.1111/tbed.12269 
17. Schumacher, L. L., Woodworth, J. C., Jones, C. K., Chen, Q., Zhang, J., Gauger, P. C., … 
Dritz, S. S. (2016). Evaluation of the minimum infectious dose of porcine epidemic diarrhea 
virus in the virus-inoculated feed. American Journal of Veterinary Research, Vol. 77, pp. 
1108–1113. https://doi.org/10.2460/ajvr.77.10.1108 
18. Scott, A., McCluskey, B., Brown-Reid, M., Grear, D., Pitcher, P., Ramos, G., … Singrey, A. 
(2016). Porcine epidemic diarrhea virus introduction into the United States: Root cause 
investigation. Preventive Veterinary Medicine, 123, 192–201. 
46 
https://doi.org/10.1016/j.prevetmed.2015.11.013 
19. Stevenson, G. W., Hoang, H., Schwartz, K. J., Burrough, E. R., Sun, D., Madson, D., … 
Yoon, K. J. (2013). The emergence of Porcine epidemic diarrhea virus in the United States: 
Clinical signs, lesions, and viral genomic sequences. Journal of Veterinary Diagnostic 
Investigation, 25(5), 649–654. https://doi.org/10.1177/1040638713501675 
20. Trudeau, M. P., Verma, H., Sampedro, F., Urriola, P. E., Shurson, G. C., & Goyal, S. M. 
(2017). Environmental persistence of porcine coronaviruses in feed and feed ingredients. 
PLoS ONE, 12(5). https://doi.org/10.1371/journal.pone.0178094 
21. Burke, M. J. (2016). Oncolytic Seneca Valley Virus: past perspectives and future directions. 
Oncolytic Virotherapy, 5, 81–89. https://doi.org/10.2147/OV.S96915 
22. Jones, C. K., Woodworth, J., Dritz, S. S., & Paulk, C. B. (2019). Reviewing the risk of feed 
as a vehicle for swine pathogen transmission. Veterinary Medicine and Science, vms3.227. 
https://doi.org/10.1002/vms3.227 
23. Zhang, X., Zhu, Z., Yang, F., Cao, W., Tian, H., Zhang, K., … Liu, X. (2018, May 11). 
Review of seneca valley virus: A call for increased surveillance and research. Frontiers in 
Microbiology, Vol. 9. https://doi.org/10.3389/fmicb.2018.00940 
24. Dokland, T. (2010, December). The structural biology of PRRSV. Virus Research, Vol. 154, 
pp. 86–97. https://doi.org/10.1016/j.virusres.2010.07.029 
25. Gauger, P. C., Faaberg, K. S., Guo, B., Kappes, M. A., & Opriessnig, T. (2012). Genetic and 
phenotypic characterization of a 2006 United States porcine reproductive and respiratory 
virus isolates associated with high morbidity and mortality in the field. Virus Research, 
163(1), 98–107. https://doi.org/10.1016/j.virusres.2011.08.017 
26. Han, G., Xu, H., & Wang, K. (n.d.). The emergence of Two different recombinants PRRSV 
strains with low neutralizing antibody susceptibility in China. 
https://doi.org/10.1038/s41598-019-39059-8 
27. Holtkamp, D. J., Kliebenstein, J. B., Neumann, E. J., Zimmerman, J. J., Rotto, H. F., Yoder, 
T. K., … Haley, C. A. (n.d.). Assessment of the economic impact of porcine reproductive and 
respiratory syndrome virus on United States pork producers. In Journal of Swine Health and 
Production. Retrieved from http://www.aasv.org/shap.html. 
28. Nelsen, C. J., Murtaugh, M. P., & Faaberg, K. S. (1999). Porcine reproductive and 
47 
respiratory syndrome virus comparison: divergent evolution on two continents. Journal of 
Virology, 73(1), 270–280. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9847330%0Ahttp://www.pubmedcentral.nih.gov/articl
erender.fcgi?artid=PMC103831 
29. Porcine Reproductive and Respiratory Syndrome (PRRS) | Iowa State University. (n.d.). 
Retrieved January 2, 2020, from https://vetmed.iastate.edu/vdpam/FSVD/swine/index-
diseases/porcine-reproductive 
30. Rossow, K. D. (1998). Porcine Reproductive and Respiratory Syndrome. Veterinary 
Pathology, Vol. 35, pp. 1–20. https://doi.org/10.1177/030098589803500101 
31. Song, D., Moon, H., & Kang, B. (2015). Porcine epidemic diarrhea: a review of current 
epidemiology and available vaccines. Clinical and Experimental Vaccine Research, 4(2), 
166. https://doi.org/10.7774/cevr.2015.4.2.166 
32. Tong, G. Z., Zhou, Y. J., Hao, X. F., Tian, Z. J., An, T. Q., & Qiu, H. J. (2007). Highly 
pathogenic porcine reproductive and respiratory syndrome, China [8]. Emerging Infectious 
Diseases, Vol. 13, pp. 1434–1436. https://doi.org/10.3201/eid1309.070399 
33. Dokland, T. (2010, December). The structural biology of PRRSV. Virus Research, Vol. 154, 
pp. 86–97. https://doi.org/10.1016/j.virusres.2010.07.029 
34. Gauger, P. C., Faaberg, K. S., Guo, B., Kappes, M. A., & Opriessnig, T. (2012). Genetic and 
phenotypic characterization of a 2006 United States porcine reproductive and respiratory 
virus isolates associated with high morbidity and mortality in the field. Virus Research, 
163(1), 98–107. https://doi.org/10.1016/j.virusres.2011.08.017 
35. Han, G., Xu, H., & Wang, K. (n.d.). The emergence of Two different recombinants PRRSV 
strains with low neutralizing antibody susceptibility in China. 
https://doi.org/10.1038/s41598-019-39059-8 
36. Holtkamp, D. J., Kliebenstein, J. B., Neumann, E. J., Zimmerman, J. J., Rotto, H. F., Yoder, 
T. K., … Haley, C. A. (n.d.). Assessment of the economic impact of porcine reproductive and 
respiratory syndrome virus on United States pork producers. In Journal of Swine Health and 
Production. Retrieved from http://www.aasv.org/shap.html. 
37. Nelsen, C. J., Murtaugh, M. P., & Faaberg, K. S. (1999). Porcine reproductive and 
48 
respiratory syndrome virus comparison: divergent evolution on two continents. Journal of 
Virology, 73(1), 270–280. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9847330%0Ahttp://www.pubmedcentral.nih.gov/articl
erender.fcgi?artid=PMC103831 
38. Porcine Reproductive and Respiratory Syndrome (PRRS) | Iowa State University. (n.d.). 
Retrieved January 2, 2020, from https://vetmed.iastate.edu/vdpam/FSVD/swine/index-
diseases/porcine-reproductive 
39. Rossow, K. D. (1998). Porcine Reproductive and Respiratory Syndrome. Veterinary 
Pathology, Vol. 35, pp. 1–20. https://doi.org/10.1177/030098589803500101 
40. Song, D., Moon, H., & Kang, B. (2015). Porcine epidemic diarrhea: a review of current 
epidemiology and available vaccines. Clinical and Experimental Vaccine Research, 4(2), 
166. https://doi.org/10.7774/cevr.2015.4.2.166 
41. Tong, G. Z., Zhou, Y. J., Hao, X. F., Tian, Z. J., An, T. Q., & Qiu, H. J. (2007). Highly 
pathogenic porcine reproductive and respiratory syndrome, China [8]. Emerging Infectious 
Diseases, Vol. 13, pp. 1434–1436. https://doi.org/10.3201/eid1309.070399 
42. Bowman, A. S., Krogwold, R. A., Price, T., Davis, M., & Moeller, S. J. (2015). Investigating 
the introduction of porcine epidemic diarrhea virus into an Ohio swine operation. BMC 
Veterinary Research, 11(1), 1–7. https://doi.org/10.1186/s12917-015-0348-2 
43. Dee, S. A., Bauermann, F. V., Niederwerder, M. C., Singrey, A., Clement, T., De Lima, M., 
… Diel, D. G. (2018). Survival of viral pathogens in animal feed ingredients under 
transboundary shipping models. PLoS ONE, 13(3). 
https://doi.org/10.1371/journal.pone.0194509 
44. Domenech, J., Lubroth, J., Eddi, C., Martin, V., & Roger, F. (2006). Regional and international 
approaches on prevention and control of animal transboundary and emerging diseases. Annals 
of the New York Academy of Sciences, 1081, 90–107. https://doi.org/10.1196/annals.1373.010 
45. Huang, C. C., Jong, M. H., & Lin, S. Y. (2000). Characteristics of Foot and Mouth Disease 
Virus in Taiwan. Journal of Veterinary Medical Science, Vol. 62, pp. 677–679. 
https://doi.org/10.1292/jvms.62.677 
46. Paarlberg, P. L., Lee, J. G., & Seitzinger, A. H. (2002). Potential revenue impact of an outbreak 
of foot-and-mouth disease in the United States. Journal of the American Veterinary Medical 
49 
Association, 220(7), 988–991. https://doi.org/10.2460/javma.2002.220.988 
47. Rossiter, P. B., & Hammadi, N. Al. (2009, September). Living with transboundary animal 
diseases (TADs). Tropical Animal Health and Production, Vol. 41, pp. 999–1004. 
https://doi.org/10.1007/s11250-008-9266-7 
48. Stegeman, A., Elbers, A., De Smit, H., Moser, H., Smak, J., & Pluimers, F. (2000). The 1997-
1998 epidemic of classical swine fever in the Netherlands. Veterinary Microbiology, 73(2–3), 
183–196. https://doi.org/10.1016/S0378-1135(00)00144-9 
49. Thompson, D., Muriel, P., Russell, D., Osborne, P., Bromley, A., Rowland, M., … Brown, C. 
(2002). Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001. 
OIE Revue Scientifique et Technique, Vol. 21, pp. 675–687. 
https://doi.org/10.20506/rst.21.3.1353 
50. Yang, P. C., Chu, R. M., Chung, W. B., & Sung, H. T. (1999). Epidemiological 
characteristicsand financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan. 
Veterinary Record, 145(25), 731–734. https://doi.org/10.1136/vr.145.25.731 
51. Ansari, I. H., Kwon, B., Osorio, F. A., & Pattnaik, A. K. (2006). Influence of N-linked 
glycosylation of porcine reproductive and respiratory syndrome virus GP5 on virus infectivity, 
antigenicity, and ability to induce neutralizing antibodies. Journal of Virology, 80(8), 3994–
4004. https://doi.org/10.1128/JVI.80.8.3994-4004.2006 
52. Charerntantanakul, W. (2012). Porcine reproductive and respiratory syndrome virus vaccines: 
Immunogenicity, efficacy and safety aspects. World Journal of Virology, 1(1), 23. 
https://doi.org/10.5501/wjv.v1.i1.23 
53. Dokland, T. (2010, December). The structural biology of PRRSV. Virus Research, Vol. 154, 
pp. 86–97. https://doi.org/10.1016/j.virusres.2010.07.029 
54. Lunney, J. K., Fang, Y., Ladinig, A., Chen, N., Li, Y., Rowland, B., & Renukaradhya, G. J. 
(2016). Porcine Reproductive and Respiratory Syndrome Virus (PRRSV): Pathogenesis and 
Interaction with the Immune System. Annual Review of Animal Biosciences, 4(1), 129–154. 
https://doi.org/10.1146/annurev-animal-022114-111025 
55. Mondaca-Fernández, E., Meyns, T., Muñoz-Zanzi, C., Trincado, C., & Morrison, R. B. (2007). 
Experimental quantification of the transmission of Porcine reproductive and respiratory 
syndrome virus. Canadian Journal of Veterinary Research, 71(2), 157–160. 
56. Nelsen, C. J., Murtaugh, M. P., & Faaberg, K. S. (1999). Porcine reproductive and respiratory 
50 
syndrome virus comparison: divergent evolution on two continents. Journal of Virology, 73(1), 
270–280. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9847330%0Ahttp://www.pubmedcentral.nih.gov/articl
erender.fcgi?artid=PMC103831 
57. Chen, Zhenhai et al. 2016. “Construction and Characterization of a Full-Length CDNA 
Infectious Clone of Emerging Porcine Senecavirus A.” Virology 497: 111–24. 
58. REED, L.J., and H. MUENCH. 1938. “A SIMPLE METHOD OF ESTIMATING FIFTY PER 
CENT ENDPOINTS12.” American Journal of Epidemiology 27(3): 493–97. 
https://academic.oup.com/aje/article-lookup/doi/10.1093/oxfordjournals.aje.a118408  
59. Pei, Yanlong et al. 2009. “Porcine Reproductive and Respiratory Syndrome Virus as a 
Vector: Immunogenicity of Green Fluorescent Protein and Porcine Circovirus Type 2 Capsid 
Expressed from Dedicated Subgenomic RNAs.” Virology 389(1–2): 91–99. 
60. Paarlberg, Philip L., John G. Lee, and Ann H. Seitzinger. 2002. “Potential Revenue Impact of 
an Outbreak of Foot-and-Mouth Disease in the United States.” Journal of the American 
Veterinary Medical Association 220(7): 988–91. 
61. Rossiter, Paul B., and Najib Al Hammadi. 2009. “Living with Transboundary Animal 
Diseases (TADs).” Tropical Animal Health and Production 41(7): 999–1004. 
62. Scott, Aaron et al. 2016. “Porcine Epidemic Diarrhea Virus Introduction into the United 
States: Root Cause Investigation.” Preventive Veterinary Medicine 123: 192–201. 
63. Stegeman, Arjan et al. 2000. “The 1997-1998 Epidemic of Classical Swine Fever in the 
Netherlands.” Veterinary Microbiology 73(2–3): 183–96. 
64. Calvert, J. G. et al. 2007. “CD163 Expression Confers Susceptibility to Porcine Reproductive 
and Respiratory Syndrome Viruses.” Journal of Virology 81(14): 7371–79. 
65. Loving, Crystal L., Fernando A. Osorio, Michael P. Murtaugh, and Federico A. Zuckermann. 
2015. “Innate and Adaptive Immunity against Porcine Reproductive and Respiratory 
Syndrome Virus.” Veterinary Immunology and Immunopathology 167(1–2): 1–14. 
66. Han, Guangwei, Huiling Xu, and Kexiong Wang. “Emergence of Two Different 
Recombinant PRRSV Strains with Low Neutralizing Antibody Susceptibility in China.” 
https://doi.org/10.1038/s41598-019-39059-8 (January 3, 2020). 
67. Baker, K. L. et al. 2017. “Systematic Epidemiological Investigations of Cases of Senecavirus 
A in US Swine Breeding Herds.” Transboundary and Emerging Diseases 64(1): 11–18. 
51 
http://doi.wiley.com/10.1111/tbed.12598 (December 24, 2019). 
68. Bowman, Andrew S. et al. 2015. “Investigating the Introduction of Porcine Epidemic 
Diarrhea Virus into an Ohio Swine Operation.” BMC Veterinary Research 11(1): 1–7. 
69. Han, Guangwei, Huiling Xu, and Kexiong Wang. “Emergence of Two Different 
Recombinant PRRSV Strains with Low Neutralizing Antibody Susceptibility in China.” 
https://doi.org/10.1038/s41598-019-39059-8 (January 3, 2020). 
70. Joshi, Lok R., Kristin A. Mohr, et al. 2016. “Detection of the Emerging Picornavirus 
Senecavirus a in Pigs, Mice, and Houseflies.” Journal of Clinical Microbiology 54(6): 1536–
45. 
71. Joshi, Lok R., Maureen H.V. Fernandes, et al. 2016. “Pathogenesis of Senecavirus a 
Infection in Finishing Pigs.” Journal of General Virology 97(12): 3267–79. 
72. Larochelle, Renée, and Ronald Magar. 1997. “Evaluation of the Presence of Porcine 
Reproductive and Respiratory Syndrome Virus in Packaged Pig Meat Using Virus Isolation 
and Polymerase Chain Reaction (PCR) Method.” Veterinary Microbiology 58(1): 1–8. 
73. Niederwerder, Megan C. et al. 2019. “Infectious Dose of African Swine Fever Virus When 
Consumed Naturally in Liquid or Feed.” Emerging Infectious Diseases 25(5): 891–97. 
74. Paarlberg, Philip L., John G. Lee, and Ann H. Seitzinger. 2002. “Potential Revenue Impact of 
an Outbreak of Foot-and-Mouth Disease in the United States.” Journal of the American 
Veterinary Medical Association 220(7): 988–91. 
75. Rossiter, Paul B., and Najib Al Hammadi. 2009. “Living with Transboundary Animal 
Diseases (TADs).” Tropical Animal Health and Production 41(7): 999–1004. 
76. Schulz, L. L., and G. T. Tonsor. 2015. “Assessment of the Economic Impacts of Porcine 
Epidemic Diarrhea Virus in the United States.” Journal of Animal Science 93(11): 5111–18. 
77. Scott, Aaron et al. 2016. “Porcine Epidemic Diarrhea Virus Introduction into the United 
States: Root Cause Investigation.” Preventive Veterinary Medicine 123: 192–201. 
78. Segalés, J. et al. 2017. “Senecavirus A: An Emerging Pathogen Causing Vesicular Disease 
and Mortality in Pigs?” Veterinary Pathology 54(1): 11–21. 
79. Stegeman, Arjan et al. 2000. “The 1997-1998 Epidemic of Classical Swine Fever in the 
Netherlands.” Veterinary Microbiology 73(2–3): 183–96. 
80. Stevenson, Gregory W. et al. 2013. “Emergence of Porcine Epidemic Diarrhea Virus in the 
United States: Clinical Signs, Lesions, and Viral Genomic Sequences.” Journal of Veterinary 
52 
Diagnostic Investigation 25(5): 649–54. 
81. Stoian, Ana M.M. et al. 2020. “Stability of Classical Swine Fever Virus and Pseudorabies 
Virus in Animal Feed Ingredients Exposed to Transpacific Shipping Conditions.” 
Transboundary and Emerging Diseases. https://www.ncbi.nlm.nih.gov/pubmed/31999072 
(February 25, 2020). 
82. Ansari, Israrul H, Byungjoon Kwon, Fernando A Osorio, and Asit K Pattnaik. 2006. 
“Influence of N-Linked Glycosylation of Porcine Reproductive and Respiratory Syndrome 
Virus GP5 on Virus Infectivity, Antigenicity, and Ability to Induce Neutralizing Antibodies.” 
Journal of virology 80(8): 3994–4004. http://www.ncbi.nlm.nih.gov/pubmed/16571816 
(March 8, 2020). 
 
 
 
 
  
 
 
 
